Terry-Ann Burrell net worth and biography

Terry-Ann Burrell Biography and Net Worth

Terry-Ann Burrell, a financial industry veteran, is Chief Financial Officer and Treasurer of Beam. Prior to Beam, Ms. Burrell spent 11 years with J.P. Morgan, most recently as a Managing Director in the healthcare investment banking group. There, she had broad coverage across the biotechnology and pharmaceutical industries, helping to execute over $10 billion in equity and equity linked financings and more than $50 billion in M&A transactions. She was instrumental in advising clients on transaction considerations, including strategic rationale, valuation and structuring, and engaged with more than 100 companies during her tenure. Prior to J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics.

Ms. Burrell holds an MBA from New York University Leonard N. Stern School of Business and a B.A. from Harvard University.

What is Terry-Ann Burrell's net worth?: The estimated net worth of Terry-Ann Burrell is at least $569,512.44 as of April 1st, 2024. Ms. Burrell owns 70,137 shares of Recursion Pharmaceuticals stock worth more than $569,512 as of April 28th. This net worth estimate does not reflect any other assets that Ms. Burrell may own. Learn More about Terry-Ann Burrell's net worth.
How do I contact Terry-Ann Burrell?: The corporate mailing address for Ms. Burrell and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Terry-Ann Burrell's contact information.
Has Terry-Ann Burrell been buying or selling shares of Recursion Pharmaceuticals?: Terry-Ann Burrell has not been actively trading shares of Recursion Pharmaceuticals in the last ninety days. Most recently, Terry-Ann Burrell sold 8,275 shares of the business's stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $12.59, for a transaction totalling $104,182.25. Following the completion of the sale, the director now directly owns 54,847 shares of the company's stock, valued at $690,523.73. Learn More on Terry-Ann Burrell's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Tina Larson (COO), Dean Li (Director), Michael Secora (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 70 times. They sold a total of 1,443,105 shares worth more than $13,646,266.83. The most recent insider tranaction occured on April, 17th when CFO Michael Secora sold 23,124 shares worth more than $175,279.92. Insiders at Recursion Pharmaceuticals own 20.0% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 4/17/2024.

Terry-Ann Burrell Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/13/2023	Sell	8,275	$12.59	$104,182.25	54,847

Terry-Ann Burrell Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $8.12

$7.68

$8.14

50 Day Range

MA: $10.37

$7.35

$15.52

2 Week Range

Now: $8.12

$4.54

$16.75

Volume

4,394,004 shs

Average Volume

4,187,155 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report